Drug Database
PI

piperacillin (piperacillin, KRKA / Isipen)

✓ Approved

Krka · Small Molecule · Small Molecule

What is piperacillin?

piperacillin is a small molecule developed by Krka. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Namespiperacillin, KRKA, Isipen
CompanyKrka
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Krka

Therapeutic Indications

piperacillin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedMedicine2026-06-09

Comparative study of piperacillin-tazobactam versus ampicillin in the treatment of severe pneumonia in children: A retrospective study.

Wang Jiangjiang J, Cao Junyi J, Zhang Lei L

Severe pneumonia remains a leading cause of pediatric mortality, with increasing β-lactamase-producing pathogens challenging traditional penicillin efficacy. This study compared the clinical efficacy and safety of piperacillin-tazobactam (PT) versus ampicillin (AMP) in children with severe community-acquired pneumonia (CAP). This retrospective cohort study with propensity score matching (PSM) enrolled children aged 6 months to 5 years with severe CAP from January 2022 to June 2024. After 1:1 PSM, 95 children per group received either PT or AMP. Primary endpoints included early clinical failure rate, end-of-therapy clinical cure rate, and sustained clinical success at test of cure (TOC). Secondary endpoints encompassed symptom resolution time, pathogen eradication rate, and safety profile. The PT group demonstrated significantly lower early clinical failure rate (2.11% vs 9.47%, P = .030; RR = 0.22, 95% CI: 0.05-0.98) and higher end-of-therapy clinical cure rate (88.17% vs 76.74%, P = .044) compared with AMP. PT achieved superior overall pathogen eradication (88.73% vs 73.13%, P = .019), particularly for Haemophilus influenzae (95.83% vs 68.00%, P = .012) and Pseudomonas aeruginosa (100.00% vs 40.00%, P = .038). Hospital stay was shorter in the PT group (8.65 ± 2.30 vs 9.81 ± 2.73 days, P = .002). Adverse event rates were comparable (10.53% vs 9.47%, P = .809). Piperacillin-tazobactam demonstrated superior efficacy over ampicillin for severe pediatric CAP, with comparable safety. These findings suggest PT offers a favorable benefit-risk profile for severe pediatric CAP, particularly in areas with documented β-lactamase-producing bacterial prevalence.

PMID 42260869
Read full article →
PubMedAntimicrobial agents and chemotherapy2026-06-09

Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants.

Morita Jun J, Sato Hiroki H, Sumiya Masayo M, Takaya Risako R et al.

We conducted an open-label study to assess the pharmacokinetics, safety, and tolerability of nacubactam-a β-lactamase inhibitor-administered alone or in combination with β-lactam antibiotic. Japanese healthy male participants received a single dose of nacubactam 2 g on Day 1, a single dose of β-lactam antibiotic (cefepime 2 g, aztreonam 2 g, meropenem 2 g, and piperacillin 4 g in Cohorts 1, 2, 3, and 4, respectively) on Day 3, and the combination of nacubactam and β-lactam antibiotic on Day 5. The study drugs were intravenously administered over 60 min. A total of 32 participants (8 in each cohort) were enrolled in the study. All participants completed the study and were included in the analysis. Exposures to nacubactam or β-lactam antibiotic (maximum plasma concentration [Cmax], area under the plasma concentration-time curve from time zero to the last quantifiable time [AUC0-t], and AUC from time zero to infinity [AUC0-∞]) were similar between the treatment periods (monotherapy vs combination therapy) in all cohorts. Coadministration of nacubactam and β-lactam antibiotic did not affect the pharmacokinetic profile of nacubactam or β-lactam antibiotic with the 90% confidence intervals for the geometric least squares mean ratios (combination therapy/monotherapy) of Cmax, AUC0-t, and AUC0-∞ contained within the equivalence range of 0.80 to 1.25 for all study drugs. Nacubactam and β-lactam antibiotics were well tolerated. All treatment emergent adverse events were mild in severity and resolved without treatment. Our results support the further clinical development of nacubactam coadministered with these β-lactam antibiotics.

PMID 42262099
Read full article →
PubMedFrontiers in physiology2026-06-08

Association between concomitant use of vancomycin-piperacillin/tazobactam and acute kidney injury in real-world setting.

Wang Chao-Hai CH, Xia Hai-Jiang HJ, Fu Yong-Ping YP, Shen Nan-Nan NN et al.

The association between acute kidney injury (AKI) and the concomitant use of vancomycin with piperacillin-tazobactam (VPT), meropenem (VM), cefepime (VC), or monotherapy with vancomycin or piperacillin-tazobactam remains controversial. This study was conducted to compare the incidence of AKI in patients receiving VPT versus those treated with vancomycin in combination with other antibiotics or as monotherapy. A comprehensive literature search was performed across PubMed, Embase, and the Cochrane library from inception up to November 30, 2025, to identify studies reporting AKI rates among patients receiving VPT or other vancomycin-based regimens. The primary outcome was the pooled incidence of AKI, which was analyzed using a random-effects model. Subgroup analyses were carried out according to geographic region and clinical setting. Thirty-five studies encompassing 39, 554 patients were included in the final synthesis. The highest pooled incidence of AKI was observed in patients receiving VPT (25.50%, 95% CI: 23.00%-28.00%), followed by VC (16.50%, 95% CI: 12.90%- 20.10%) and VM (14.00%, 95% CI: 8.90-19.20). Lower incidence rates were reported with vancomycin monotherapy (8.10%, 95% CI: 5.80%-10.40%) and piperacillin- tazobactam alone (12.30%, 95% CI: 6.70%-17.90%). Subgroup analysis showed that ICU patients experienced significantly higher AKI rates when receiving VPT (33.80%, 95% CI: 29.80%-37.70%) compared to non-ICU patients (17.20%, 95% CI: 15.80% -18.60%), a trend also observed with piperacillin- tazobactam monotherapy (P < 0.05). Geographically, patients in Europe exhibited a markedly higher risk of AKI with VPT (41.30%, 95% CI: 29.10%-53.50%) than those in North America (25.40%, 95% CI: 22.80-28.10) or Asia (24.80%, 95% CI: 14.60-35.00). Nevertheless, this result from European population was only based on one study, it needs to be interpreted carefully. Similarly, the risk of nephrotoxicity with vancomycin monotherapy was higher in European populations (15.70%) compared to North American (8.40%) and Asian (4.00%) patients. This study suggests that VPT is linked to the highest risk of AKI compared to other vancomycin-containing regimens, including beta-lactam combinations and monotherapies. These findings highlight the importance of prudent antibiotic selection and rigorous renal monitoring, particularly in critically ill patients.

PMID 42255521
Read full article →
PubMedFrontiers in pharmacology2026-06-08

Thrombocytopenia and anemia associated with piperacillin-tazobactam: integrating clinical case series with FAERS disproportionality analysis.

Lu Jing J, Yang Guoshang G, Liang Shengjun S, Yang Qifeng Q et al.

Piperacillin-tazobactam (TZP) is a commonly used broad-spectrum antibiotic in clinical practice; however, its haematopoietic toxicity profile has not yet been fully elucidated. This study combines clinical case observations with large-scale pharmacovigilance data to characterize TZP-associated thrombocytopenia and anemia. We first report a case series of three patients presenting with distinct TZP-associated haematopoietic injuries, including severe thrombocytopenia complicated by mild anemia, as well as mixed haematopoietic toxicity predominantly manifested as anemia, with or without concomitant thrombocytopenia. Subsequently, a disproportionality analysis was performed on the FDA Adverse Event Reporting System (FAERS) database using four quantitative methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). The disproportionality analysis confirmed a significant and robust risk signal for TZP-associated thrombocytopenia (ROR = 5.26, 95% CI 4.81-5.74), which remained stable in sensitivity analyses adjusting for concomitant medications. Although the signal for anemia was relatively weak across all methods, the clinical cases provided key evidence supporting the occurrence of this adverse reaction. TZP can induce severe thrombocytopenia. It is recommended to actively monitor complete blood counts, with particular attention to platelet, erythrocyte, and hemoglobin levels, within the first week of treatment initiation. When encountering unexplained cytopenia in clinical practice, TZP should be considered as a potential causative agent; if the drug is highly suspected, immediate discontinuation is warranted.

PMID 42256409
Read full article →
PubMedIJU case reports2026-06-08

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma.

Soga Erika E, Noguchi Go G, Kobayashi Kota K, Shibata Rio R et al.

Lenvatinib plus pembrolizumab is a standard first-line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event. A 60-year-old woman with metastatic TFE3-positive non-clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (IMDC) criteria, started pembrolizumab plus lenvatinib after palliative radiotherapy for cervical spine metastasis. Lenvatinib was initiated at 8 mg and escalated to 12 mg, achieving tumor shrinkage. Nine days after starting cycle 4, she developed fever and right upper quadrant pain. Computed tomography demonstrated gallbladder distension and wall thickening without gallstones, consistent with acute acalculous cholecystitis. Lenvatinib was interrupted, and intravenous piperacillin/tazobactam was administered; her symptoms improved without drainage. Lenvatinib was resumed at 8 mg with pembrolizumab, and no recurrence occurred. Early recognition and temporary interruption of lenvatinib with antibiotics may allow cautious rechallenge.

PMID 42256328
Read full article →
PubMedFrontiers in medicine2026-06-08

Analysis of pathogen distribution and association with lipid levels in patients with diabetic foot.

Chen Yan Y, Chen Weihong W, Zhuo Yinxia Y

Diabetic foot infection (DFI) is a severe complication of diabetes, and dyslipidemia is common in affected patients. However, the relationship between lipid profiles, pathogen distribution, and antimicrobial resistance in DFI remains unclear. This retrospective study analyzed clinical and microbiological data from 85 patients with diabetic foot treated between January 2021 and August 2024. Lipid parameters (total cholesterol, triglycerides, HDL-C, and LDL-C) were recorded. Pathogens were identified using routine culture and biochemical methods, and antimicrobial susceptibility was assessed by disk diffusion according to CLSI guidelines. Gram-positive bacteria predominated (54.12%), followed by gram-negative bacteria (38.82%), with Staphylococcus aureus and Pseudomonas aeruginosa being the most common isolates. Gram-positive bacteria showed the highest susceptibility to linezolid and vancomycin, whereas gram-negative bacteria were most sensitive to amikacin and piperacillin-tazobactam. No significant differences were observed in lipid levels among different pathogen groups, or between drug-resistant and non-resistant or multidrug-resistant and non-multidrug-resistant infections (all p > 0.05). Lipid profiles were not significantly associated with pathogen distribution or antimicrobial resistance patterns in patients with diabetic foot infection. Further prospective studies are needed to clarify the role of lipid metabolism in infection susceptibility and clinical outcomes.

PMID 42254360
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about piperacillin